Trump announces 30% tariffs against EU, Mexico to begin August 1
BRIDGEWATER, New Jersey — U.S. President Donald Trump on Saturday announced he's levying tariffs of 30 per cent against the European Union and Mexico.
Trump announced the tariffs on two of the United States' biggest trade partners in letters posted to his social media account.
In his letter to Mexico's leader, Trump acknowledged that the country has been helpful in stemming the flow of undocumented migrants and fentanyl into the United States.
But he said the country has not done enough to stop North America from turning into a 'Narco-Trafficking Playground.'
Aamer Madhani, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion by the end of the decade. Oncology, at present, comprises around 27% of J&J's total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches. Though the $50 billion target was well above consensus, J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. Meanwhile, J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ's oncology sales. In the five years from 2019 to 2024, J&J's oncology sales have doubled from $10.7 billion in 2019 to $20.8 billion in 2024. To achieve the $50 billion target in the next 5-6 years, the company needs to more than double its sales from 2024 levels. Though quite optimistic, the target is not unachievable. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK and Bristol-Myers. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. For AstraZeneca, oncology sales now comprise around 41% of total revenues. AstraZeneca's strong oncology sales growth is being driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI1inhibitor, Opdivo, which accounts for around 20% of its total revenues. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 14.6% in the year-to-date period compared with an increase of 1.5% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.97 forward earnings, slightly lower than 15.04 for the industry. The stock is also trading below its five-year mean of 15.70. The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.66 over the past 30 days, while that for 2026 has risen from $10.98 to $11.13 over the same timeframe. J&J has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Globe and Mail
7 minutes ago
- Globe and Mail
EverCommerce Announces Date of Second Quarter 2025 Earnings Call
DENVER, July 18, 2025 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ: EVCM), a leading provider of SaaS solutions for service SMBs, will report its second quarter 2025 financial results after the U.S. financial markets close on Thursday, August 6, 2025. Management will host a conference call on Wednesday, August 6 at 5:00 p.m. Eastern Time / 3:00 p.m. Mountain Time to discuss the Company's financial results and provide a business update. Please visit the 'Investor Relations' page of the Company's website ( for both telephonic and webcast access to this call; a replay will be archived on the website as well. About EverCommerce EverCommerce (Nasdaq: EVCM) is a leading service commerce platform, providing vertically-tailored, integrated SaaS solutions that help more than 725,000 global service-based businesses accelerate growth, streamline operations, and increase retention. Its modern digital and mobile applications create predictable, informed, and convenient experiences between customers and their service professionals. With its EverPro, EverHealth, and EverWell brands specializing in Home, Health, and Wellness service industries, EverCommerce provides end-to-end business management software, embedded payment acceptance, marketing technology, and customer experience applications. Learn more at
CTV News
7 minutes ago
- CTV News
Sudbury contributes land to federally protected areas database
Politicians, environmentalists and Indigenous representatives gathered Thursday to announce Sudbury's contribution to Canada's 30 by 30 goal.
